Connect with us
European Gaming Congress 2024

Artificial Intelligence

Neoantigens Personalized Cancer Vaccine Clinical Trials Insight

Published

on

Delhi, July 05, 2022 (GLOBE NEWSWIRE) — Global Personalized Cancer Vaccine Market Outlook 2028 Report Highlights:

  • Developmental Cost Analysis of a Personalized Cancer Vaccine
  • Biomarkers Importance  In Personalized Vaccines
  • Ongoing Clinical Trials on Personalized Cancer Vaccine
  • Immune Checkpoint Biomarkers Preventing Tumor Growth
  • Personalized Cancer Vaccine Market Dynamics
  • Advancements in the Personalized Cancer Vaccine
  • Ongoing Market Trends in Personalized Cancer Vaccine Market

Download Report
 https://www.kuickresearch.com/report-personalised-cancer-vaccines-market-trials

The field of immunotherapy has greatly transformed the management of several cancers with the development and regulatory approval of various immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies in diverse indications. Personalized vaccine is another novel immunotherapeutic approach which triggers de novo T cell responses against neoantigens, which are highly specific to tumors of individual patients. Although, no personalized vaccine has entered the global market, the pipeline is highly crowded suggesting encouraging future of this therapeutics in the management of cancer.

In contrast to vaccines targeting tumor associated antigens, personalized vaccine targeting neoantigens confer several advantages. As neoantigens are solely expressed on the tumor cells and therefore these vaccines elicit tumor specific T cell response and therefore prevent off-target toxicity on normal cells. In addition, the personalized vaccine boost neoantigen specific T cell response which persists for longer and provide post-treatment immunological memory, thus protecting from cancer for longer term and reduces the chance of disease recurrence. Owing to several advantages, personalized vaccines have gained significant interest from scientists, research institutions, and pharmaceutical companies which can be reflected in their novel pipeline.

The key players in the market include Neon Therapeutics, Medigene, OSE Immunotherapeutics, Gristone Oncology, Nouscom, Roche, Moderna, and others. The company’s pipeline product is rapidly reporting encouraging results. For instance, Moderna in collaboration with Merck has developed its novel mRNA personalized cancer vaccine (PCV), mRNA4157 which is combination of validated defined neoantigens, predicted neoepiotopes and mutations in driver genes into a single mRNA concatemer (mRNA4650). The vaccine is being evaluated as monotherapy and combination therapy in two clinical trials. The initial data from the trial demonstrates that the vaccine when given alone or in combination was well tolerated at all doses tested and elicited neoantigen specific T cell responses.

Further, the collaboration between BioNTech and Genentech has led to development of iNeST (individualized Neoantigen Specific immunotherapy) program candidate autogene cevumeran (BNT122). Recently, the companies reported encouraging results from phase-I study evaluating the combination of autogene cevumeran with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). After a median follow-up of 18 months, patients with de-novo immune response showed significantly longer recurrence-free survival (RFS) as compared to those without vaccine-induced immune responses. On the basis of this encouraging data, the company will initiate further clinical trials.

Advertisement

The companies have also adopted strategic alliance to maintain a strategic edge in the global market. For instance in 2022, physIQ entered into collaboration with CellCarta to potentially transform the vaccine development through a more personalized and precise approach. Under the terms, company will initiate VIII (Vaccine-Induced Inflammation Investigation) study which will focus on early, individualized human responses to vaccines as pharmaceutical companies release vaccines at a faster pace. During this, the physiology and immune system activation will be monitored remotely at all times using medical-grade biosensors. The novel artificial intelligence based digital platform and immunologic biomarkers will enable personalized baselines to be established by detecting subtle changes within hours after vaccination.

The major factors propelling the growth of market include rise in prevalence of various types of cancer, fewer side effects of personalized vaccine, and robust pipeline of innovative vaccines in development. In addition, advancement in the field of genomics and rising interest in identification of biomarkers for developing novel therapies is also driving the growth of market during the forecast period. However, the lack of consumer awareness as well as stringent regulatory guidelines will restrain the growth of market.  


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

18 of the Top 20 Medtech Companies Partner with Veeva MedTech to Get Devices and Diagnostics to Patients Faster

Published

on

18-of-the-top-20-medtech-companies-partner-with-veeva-medtech-to-get-devices-and-diagnostics-to-patients-faster

More than 125 medtech customers use Veeva applications for seamless execution across product development
BARCELONA, Spain, Oct. 2, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that 18 of the top 20 medtech companies leverage Veeva Development Cloud and Veeva Commercial Cloud applications to streamline processes across the total medtech product lifecycle. Veeva MedTech enables more than 125 customers with deep industry expertise and technology from ideation to commercialization. With an increasing need to keep up with industry changes for faster time to market, medtech companies are moving to connected applications on a single cloud platform to execute key processes more efficiently.

“With dozens of studies across hundreds of global sites, simplifying clinical operations with unified document management and streamlined workflows is a top priority,” said Matt Christensen, senior vice president at Smith+Nephew. “Using Veeva MedTech’s unified clinical solution drives transparency, ensures integrity of study files, and speeds trial timelines.”
Veeva MedTech enables end-to-end product lifecycle management with Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Quality, and Veeva Vault Commercial. Using advanced applications built with medtech industry best practices, customers can access real-time insights to make data-driven decisions, automate processes, and maintain inspection readiness. This reduces manual work and improves cross-team collaboration while driving growth, cost efficiency, and compliance.
“This momentum shows that the global medtech industry has made great strides in modernizing systems, establishing a foundation across the product lifecycle to leverage into the future,” said Seth Goldenberg, vice president, Veeva MedTech. “With the top medtech leaders standardizing on Veeva applications, we will continue to learn and advance the industry toward more streamlined processes to deliver innovative new devices and diagnostics to patients in need.”
More than 200 industry professionals will network, share best practices, and hear valuable insights from medtech leaders, including Bio-Rad Laboratories, Philips, and ZEISS Medical Technology, at Veeva MedTech EU Summit. Medtech industry professionals can register for the Nov. 5 – 7 event in Amsterdam.
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy WhittakerVeeva [email protected]
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/18-of-the-top-20-medtech-companies-partner-with-veeva-medtech-to-get-devices-and-diagnostics-to-patients-faster-302265339.html

Continue Reading

Artificial Intelligence

Cybersecurity is fastest growing IT occupation in the UK, reveals Socura report

Published

on

cybersecurity-is-fastest-growing-it-occupation-in-the-uk,-reveals-socura-report

But skills gap persists with just one security professional for every 86 companies
CARDIFF, Wales, Oct. 2, 2024 /PRNewswire/ — Socura, a UK-based cybersecurity services business that protects many of the nation’s biggest NHS trusts, councils, and private companies, has released its UK cybersecurity careers 2024 report, ‘Their next job was in cyber’. 

The report is released four years after the UK government’s infamous ‘Fatima’ ballet ad promoting cyber as a career option. Based on Office of National Statistics data, it reveals that cybersecurity is now the fastest growing tech occupation in the UK, with the number of people in cyber roles more than doubling (128%) between 2021 and 2024. Despite this growth rate, there are not yet enough cybersecurity professionals to tackle the growing threat to UK businesses, with only one security pro for every 86 companies. 
Other key findings of Socura’s report include: 
There are 4,600 more women in cybersecurity roles in 2024 compared to 2021. However, the percentage of women in cybersecurity roles has decreased and now stands at 17%, down from 24%. London is less of a hub for cybersecurity professionals than it is for other IT professionals. 25% of all IT workers are based in London, compared to 17% of cyber workers.Northern Ireland and Wales are the countries in the UK with the fewest cybersecurity professionals. “Cybersecurity may be the fastest growing IT occupation in the UK but the skills shortage in the industry remains a concern,” said Andy Kays, CEO at Socura. “Many businesses simply do not have the specialists they need to defend against cyber attacks.  
“To fix this problem at a national level, we need more initiatives like the NCSC-backed Academic Centres of Excellence and ways to reach even younger people so that they can discover technology in schools. For organisations struggling to recruit cybersecurity experts, finding a trusted managed services partner to bolster capabilities and ease the load remains vital to bridging the gap.” 
“Attracting more workers, particularly women, into cyber remains a key challenge for the industry,” said Dr Kathryn Jones, Head of School, Computer Science and Informatics at Cardiff University. ”However, gender imbalance and the low representation of women is a wider issue in the tech sector, not only cybersecurity. The number of women enrolled on computer science and software engineering courses, for example, is typically also low.  
“Cybersecurity is an exciting and varied career choice but more initiatives like the NCSC’s Cyber First Girls competition are needed to raise awareness.” 
Resources 
Read summary blogDownload full report Methodology Socura’s analysis is based on UK ONS annual population survey data, which tracks occupation figures based on 15 IT-related Standard Occupational Classification (SOC2020) codes such as 2135 cybersecurity professionals. The ONS annual population is a continuous survey that consists of 12 months of survey data, which is broken down and released on a quarterly basis. 
About Socura Socura reduces cyber risk by proactively detecting and responding to threats, 24/7. Our Managed Detection and Response (MDR) service operates as an extension of an organisation’s security team – supplying highly skilled SOC experts and the additional capabilities needed to scale security operations and accelerate response to attacks. 
Image – https://mma.prnewswire.com/media/2521615/Their_Next_Job_was_in_Cyber.jpgLogo – https://mma.prnewswire.com/media/2449813/Socura_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/cybersecurity-is-fastest-growing-it-occupation-in-the-uk-reveals-socura-report-302265485.html

Continue Reading

Artificial Intelligence

Euromonitor International launches Passport AI – a gamechanger for the data analysis industry

Published

on

euromonitor-international-launches-passport-ai-–-a-gamechanger-for-the-data-analysis-industry

Passport AI will leverage the power of generative AI to transform the way our clients’ access and use market intelligencePassport AI’s impressive features, combining cutting-edge artificial intelligence with human intelligence, will ensure fast and easy access to the Passport platform Paradigm shift solution utilises a powerful combination of technologies and approachesLONDON, Oct. 2, 2024 /PRNewswire/ — Euromonitor International has today launched Passport AI – a game changer for the data analysis industry.

Passport AI is specially designed to supercharge the power of data analytics firm Euromonitor International’s market intelligence expertise. The platform will leverage the power of generative AI to transform the way clients are able to access and use Euromonitor’s market intelligence.
Euromonitor’s Passport AI utilises a powerful combination of technologies and approaches: 
Large Language Models (LLMs): These powerful AI models are trained on massive amounts of text data. Passport AI leverages LLMs to understand your natural language questions and identify relevant information within our extensive content library.Retrieval Augmented Generation (RAG): This approach ensures Passport AI stays grounded in fact-based information. Instead of creating entirely new responses, RAG retrieves and summarises relevant content from trusted Euromonitor publications. This allows clients to verify the source of the information and feel confident in its reliability. Multi-Agent System (MAS): This innovative system acts behind the scenes, working like a team of virtual researchers. MAS helps Passport AI refine your question and identify the most relevant information across our content, even with terminology specific to Passport or newly introduced natural language search. Combining cutting-edge artificial intelligence with human intelligence
Lamine Lahouasnia, Director of Generative AI at Euromonitor International, said: “We are already the first destination for organisations seeking growth and Passport AI’s impressive features, combining cutting-edge artificial intelligence with human intelligence, will ensure fast and easy access to our Passport product and our data analytics.
“Unlike other generative AI tools, the information provided by Passport AI is 100% sourced from Euromonitor’s trusted content. This transparency allows users to interrogate the underlying sources and have complete confidence in the credibility of the answers they receive.”
Tim Kitchin, CEO of Euromonitor International, said: “This significant investment in Passport AI underscores our dedication to client empowerment and demonstrates our commitment to continuous product improvement. We believe Passport AI will help clients derive even more value from the intelligence they already have access to within Passport, make the most of opportunities our insights uncover and achieve greater success.”
For more information about Passport AI book a demo.

View original content:https://www.prnewswire.co.uk/news-releases/euromonitor-international-launches-passport-ai–a-gamechanger-for-the-data-analysis-industry-302265417.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending